Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus, Cyclosporine, and MMF for GVHD Prevention in Mismatched Donor HCT
NCT01251575Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2010
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of Acute Graft Versus Host Disease Grades II-IV. Started Dec 2010; status: completed.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01251575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251575.